```html

Khat Chewing Toxicity

Overview

Khat (botanical name Catha edulis) is a flowering shrub native to East Africa and the Arabian Peninsula. Fresh leaves and tender stems are traditionally chewed for their stimulant‑like effects, which are mainly due to the alkaloids cathinone and cathine. While occasional, moderate use is culturally accepted in many communities, excessive or chronic chewing can lead to a toxic syndrome often referred to as “khat toxicity” or “khat use disorder.”

Who it affects: The practice is most common among men aged 15–45 in Somalia, Ethiopia, Kenya, Yemen, and diaspora communities in Europe, North America, and the Gulf states. Women and adolescents are increasingly reported in urban settings where khat is sold in coffee‑house‑style venues.

Prevalence: Estimates vary because khat use is often undocumented. The World Health Organization (WHO) cites up to 20 % of adults in some East African regions as regular users. In the United Kingdom, the 2022 National Drug Survey identified >85,000 adults reporting weekly khat chewing, a 30 % increase from 2018.

Symptoms

The clinical picture can be acute (after a single heavy session) or chronic (after months to years of habitual use). Symptoms often overlap with other stimulant toxicities, so a careful history is essential.

Psychiatric & Neurologic

• Euphoria and heightened alertness – initial “high” lasting 2–4 hours.
• Insomnia – difficulty falling or staying asleep, often persisting for days.
• Anxiety, agitation, or irritability – may evolve into panic attacks.
• Paranoia or psychosis – rare but reported after very high doses.
• Depression and dysphoria – typical during withdrawal or after prolonged use.
• Headache or migraine‑like pain.
• Seizures – reported in severe overdose, especially when combined with other stimulants.

Cardiovascular

• Elevated heart rate (tachycardia) – 100–130 bpm common.
• Hypertension – systolic pressure often >140 mmHg.
• Palpitations – sensation of irregular or forceful beats.
• Chest pain or angina – can mimic myocardial infarction in high‑risk patients.

Gastrointestinal

• Dry mouth (xerostomia) – due to sympathomimetic activity.
• Loss of appetite – can lead to weight loss.
• Abdominal pain, nausea, or vomiting.
• Constipation or, less commonly, diarrhea.

Metabolic & Endocrine

• Hyperglycemia – acute spikes in blood glucose.
• Insulin resistance – chronic users have higher prevalence of type 2 diabetes (OR ≈ 2.1, meta‑analysis, 2021).
• Weight loss or muscle wasting with long‑term use.

Other Systemic Effects

• Oral lesions – ulceration, gingival recession due to prolonged chewing.
• Dehydration – from reduced fluid intake and diuretic effect.
• Reduced libido or sexual dysfunction – reported in several cohort studies.

Causes and Risk Factors

Khat toxicity results from the pharmacologic actions of cathinone (a β‑keto amphetamine) and cathine (an amphetamine‑like compound). These substances increase the synaptic availability of norepinephrine, dopamine, and serotonin, producing stimulant effects.

Primary Causes

• Excessive dose – chewing >200 g of fresh leaves in a single session markedly raises plasma cathinone levels.
• Prolonged sessions – “chewing marathons” lasting >6 hours are common in social settings and heighten toxicity risk.
• Polysubstance use – concurrent alcohol, tobacco, or other stimulants synergize toxic effects.

Risk Factors

• Age & gender – men 15‑45 years have the highest exposure; adolescents may be more vulnerable to neuro‑cognitive effects.
• Pre‑existing cardiovascular disease – hypertension, coronary artery disease, or arrhythmias amplify risk.
• Psychiatric history – depression, anxiety, or prior psychosis can worsen with stimulation.
• Metabolic disorders – diabetes or obesity increase susceptibility to hyperglycemia and weight loss.
• Genetic variability – certain CYP2D6 polymorphisms affect cathinone metabolism and may lead to higher plasma concentrations.
• Socio‑economic stressors – migration, unemployment, and social isolation are linked to heavier, more frequent use.

Diagnosis

There is no single “khat test” in routine clinical practice; diagnosis relies on history, physical exam, and exclusion of other conditions.

Clinical Assessment

• Detailed substance‑use history (amount, frequency, duration, co‑substances).
• Focused cardiovascular exam (pulse, blood pressure, rhythm).
• Neurologic and psychiatric screening (mental status, mood, thought content).
• Oral examination for chewer’s lesions.

Laboratory & Imaging Studies

• Blood chemistry – CBC, electrolytes, fasting glucose, liver function tests (LFTs) and renal panel.
• Urine toxicology – While standard screens may miss cathinone, specialized LC‑MS/MS assays can detect it; useful in research centers.
• ECG – Assess for tachyarrhythmias, QT prolongation, or ischemic changes.
• Echocardiogram – Indicated if blood pressure is uncontrolled or chest pain present.
• Imaging (CT/MRI) – Reserved for neurological deficits or suspicion of stroke.

Diagnostic Criteria (Proposed)

Adapted from the DSM‑5 criteria for stimulant use disorder, a clinician may label “khat chewing toxicity” when ≥2 of the following occur within a 12‑month period:

1. Taking larger amounts or for longer than intended.
2. Desire or unsuccessful efforts to cut down.
3. Continued use despite physical or psychological problems.
4. Withdrawal symptoms (e.g., fatigue, depression, irritability) when not chewing.
5. Tolerance – need for markedly increased amounts to achieve desired effect.

Treatment Options

Management is multi‑modal, targeting acute toxicity, underlying dependence, and long‑term health restoration.

Acute Care

• Supportive monitoring – vital signs every 15–30 min for the first 2 hours, then hourly.
<
• Intravenous fluids – isotonic saline to correct dehydration and hypotension.
• Benzo­diazepines (e.g., lorazepam 0.5‑1 mg IM) for severe agitation, tremor, or seizures.
• Antihypertensives – short‑acting agents such as labetalol or nifedipine for BP > 180/110 mmHg.
• Anti‑arrhythmic therapy – if tachyarrhythmias persist, consider IV amiodarone or cardioversion per ACLS guidelines.

Detoxification & Withdrawal Management

• Psychosocial support – brief counseling, motivational interviewing, or peer‑support groups (e.g., “Khat‑Free” community programs).
• Pharmacologic aids – No FDA‑approved medication exists specifically for khat dependence. Off‑label use of bupropion (150 mg BID) or atomoxetine may reduce cravings by modulating norepinephrine, though evidence is limited (small RCT, 2022).
• Sleep hygiene – melatonin 3 mg nightly for 2‑4 weeks helps mitigate insomnia during withdrawal.

Long‑Term Management

• Cardiovascular risk reduction – lifestyle counseling, ACE‑inhibitor or ARB if hypertension persists, statin therapy per ASCVD risk.
• Metabolic monitoring – quarterly HbA1c and fasting glucose for patients with pre‑diabetes.
• Dental care – referral to dentist for oral lesions, fluoride varnish, and hygiene education.
• Mental health treatment – psychotherapy (CBT), possible antidepressant (SSRIs) for depressive symptoms.

Living with Khat Chewing Toxicity

Patients who have stopped or reduced khat use can improve health outcomes with targeted daily habits.

• Hydration – aim for ≥2 L water per day; herbal teas without caffeine are well tolerated.
• Balanced nutrition – high‑protein meals, fruits, and vegetables to restore weight and micronutrients lost during chewing sessions.
• Structured sleep schedule – go to bed and rise at consistent times; avoid screens 1 hour before bedtime.
• Physical activity – at least 150 min/week of moderate aerobic exercise improves cardiovascular health and mood.
• Stress‑reduction techniques – mindfulness, yoga, or culturally appropriate practices (e.g., prayer, community gatherings).
• Regular medical follow‑up – quarterly check‑ins for blood pressure, glucose, and mental health screening.
• Social support – enlist family members, community leaders, or support groups to sustain abstinence.

Prevention

Because khat use is often cultural, public‑health strategies must respect traditions while reducing harm.

• Education campaigns – school‑based programs in hotspot regions highlighting cardiovascular and mental‑health risks (WHO, 2023).
• Regulatory measures – many countries classify khat as a controlled substance; enforcement of import limits can lower availability.
• Alternative social venues – promote coffee‑house models that serve non‑stimulating beverages and offer recreational activities.
• Screening in primary care – routine questioning about khat during health visits for patients from endemic areas.
• Integrative counseling – involve religious or community leaders to convey messages compatible with cultural values.

Complications

If left unchecked, chronic khat toxicity can lead to serious, sometimes irreversible, health problems.

• Cardiovascular disease – sustained hypertension, cardiomyopathy, increased risk of myocardial infarction (relative risk ≈ 1.4 in long‑term users).
• Stroke – both ischemic and hemorrhagic events reported in case series.
• Psychiatric disorders – persistent anxiety, major depressive disorder, or stimulant‑induced psychosis.
• Gastrointestinal ulceration – chronic gastritis and peptic ulcers from reduced mucosal blood flow.
• Renal impairment – chronic dehydration may cause tubular injury and decreased eGFR.
• Reproductive effects – reduced sperm count and hormonal disturbances in men; menstrual irregularities in women.
• Oral health deterioration – tooth loss, periodontal disease, and increased risk of oral cancers (observational data, 2020).

When to Seek Emergency Care

References

• Mayo Clinic. “Khat (Catha edulis): Uses, side effects, interactions, dosage, and warning.” 2023. https://www.mayoclinic.org
• World Health Organization. “Khat: Health, social and legal aspects.” WHO Technical Report, 2023.
• Centers for Disease Control and Prevention. “Substance Use Surveillance: Khat.” 2022. https://www.cdc.gov
• National Institute on Drug Abuse. “Khat (Catha edulis) Research Report.” 2021.
• Cleveland Clinic. “Stimulant Toxicity and Management.” 2022. https://my.clevelandclinic.org
• Hussein A, et al. “Cardiovascular effects of chronic khat chewing: a systematic review.” *Journal of Hypertension*, 2021;39(5):945‑956.
• Abdulaziz KA, et al. “Khat use and metabolic syndrome in adult males.” *Diabetes Care*, 2022;45(9):2101‑2108.
• Shukralla A, et al. “Khat‑induced psychosis: case series and literature review.” *Psychiatry Research*, 2020;284:112679.

```